These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2007364

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
    Rosenoff S.
    Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Octreotide therapy in AIDS-related, refractory diarrhea: results of a multicentre Canadian-European study. Octreotide International Multicentre AIDS-Diarrhea Study.
    Montaner JS, Harris AG.
    AIDS; 1995 Feb; 9(2):209-10. PubMed ID: 7718196
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation.
    Morton AJ, Durrant ST.
    Clin Transplant; 1995 Jun; 9(3 Pt 1):205-8. PubMed ID: 7549062
    [Abstract] [Full Text] [Related]

  • 26. Effect of octreotide on small intestinal motility in HIV-infected patients with chronic refractory diarrhea.
    Neild PJ, Evans DF, Castillo FD, Newson R, Yasaki ET, Wingate DL, Gazzard BG.
    Dig Dis Sci; 2001 Dec; 46(12):2636-42. PubMed ID: 11768253
    [Abstract] [Full Text] [Related]

  • 27. Diarrhea and the rationale to use Sandostatin.
    Peeters M, Van den Brande J, Francque S.
    Acta Gastroenterol Belg; 2010 Dec; 73(1):25-36. PubMed ID: 20458847
    [Abstract] [Full Text] [Related]

  • 28. The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study.
    Yavuz MN, Yavuz AA, Aydin F, Can G, Kavgaci H.
    Int J Radiat Oncol Biol Phys; 2002 Sep 01; 54(1):195-202. PubMed ID: 12182992
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS.
    Clin Endocrinol (Oxf); 1999 Feb 01; 50(2):245-51. PubMed ID: 10396369
    [Abstract] [Full Text] [Related]

  • 31. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR, van den Oever NC, Frölich M, Arias AM, Smit JW, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2003 Mar 01; 58(3):288-95. PubMed ID: 12608933
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients.
    Geller RB, Gilmore CE, Dix SP, Lin LS, Topping DL, Davidson TG, Holland HK, Wingard JR.
    Am J Hematol; 1995 Nov 01; 50(3):167-72. PubMed ID: 7485077
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Treatment of endocrine and nonendocrine secretory diarrheal states with Sandostatin.
    Gaginella TS, O'Dorisio TM, Fassler JE, Mekhjian HS.
    Metabolism; 1990 Sep 01; 39(9 Suppl 2):172-5. PubMed ID: 2205786
    [Abstract] [Full Text] [Related]

  • 37. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P.
    Cancer; 2000 Feb 15; 88(4):770-6. PubMed ID: 10679645
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.
    Lancranjan I, Atkinson AB.
    Pituitary; 1999 Feb 15; 1(2):105-14. PubMed ID: 11081188
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.